Compare Quest Diagnostics Inc (DGX) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Halliburton Company — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Halliburton Company trades at $35.52 (market cap $29.59B). The key difference: Halliburton Company is the larger of the two by market cap, and Halliburton Company pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| DGX | HAL | |
|---|---|---|
Market Cap | $22.80B | $29.59B |
Sector | Health | Energy |
52-Week High | $216.02 | $42.98 |
52-Week Low | $166.42 | $20.50 |
Enterprise Value | $28.82B | $35.67B |
Dividend Yield | 1.67% | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Halliburton (HAL) trades at $35.21, up 2.38% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a major contract win offshore Suriname highlight operational strength, though net income declined in 2025. The stock shows solid profitability with a 6.95% net margin and 14.56% ROE, supported by positive cash flow trends into 2026.
The outlook remains positive given analyst targets near $44.78 and ongoing energy sector tailwinds, but risks include oil price volatility and execution challenges. Earnings growth and contract execution are key catalysts for further upside, balancing macroeconomic and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
